Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

VitusCare has developed proprietary playbooks to find the right hospital partners, fast-track centre-launches and use ...

A phase 1 trial of a personalized cancer vaccine for stage III/IV clear cell renal cell carcinoma showed promising results.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

VANCOUVER — Transit workers in British Columbia's Cowichan Valley have launched strike action, shutting down services in the ...

Objectives Patients with SLE take multiple medications. Within a large prospective longitudinal SLE cohort, we characterised ...

Like most people who have been diagnosed with a life-threatening disease, Ruel Bautista is still trying to come to terms with his situation although he still wonders why fate dealt him such a hand. “I ...